Medicus Pharma director granted 25,000 stock options

Medicus Pharma Ltd. director Patrick J. Mahaffy received a compensation-related stock option grant, not an open-market trade.

Accepted by SEC EDGAR 04/01/2026 - 07:14 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Medicus Pharma Ltd. director Patrick J. Mahaffy received a compensation-related stock option grant, not an open-market trade. He was granted options to acquire 25,000 common shares at an exercise price of $0.50 per share. These options become exercisable on March 26, 2027 and are scheduled to expire on March 27, 2031. Following this grant, he holds options for 25,000 shares directly.

Insider Trade Summary

Grant/Award: 25,000 shares

Grant/Award 1 txn

Insider MAHAFFY PATRICK J

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	25,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 25,000 contracts (Direct)

Key Figures

Options granted: 25,000 options Exercise price: $0.50 per share Shares underlying options: 25,000 common shares +3 more

6 metrics

Options granted 25,000 options Stock Option (right to buy) grant

Exercise price $0.50 per share Option strike price

Shares underlying options 25,000 common shares Underlying security

Exercise date March 26, 2027 Options become exercisable

Expiration date March 27, 2031 Options lapse if unexercised

Options held after transaction 25,000 options Total derivative holdings reported

Key Terms

Stock Option (right to buy), grant/award acquisition, exercise price, expiration date, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: "Stock Option (right to buy)""

grant/award acquisition financial

"transaction_action: "grant/award acquisition""

exercise price financial

"conversion_or_exercise_price: "0.5000""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: "2031-03-27T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

underlying security financial

"underlying_security_title: "Common Shares""

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Medicus Pharma (MDCX) report for Patrick J. Mahaffy?

Medicus Pharma reported that director Patrick J. Mahaffy received a grant of stock options for 25,000 common shares. This was a compensation-related award, not an open-market purchase or sale of existing shares.

At what price can the new Medicus Pharma (MDCX) options be exercised?

The granted stock options have an exercise price of $0.50 per share. This means Mahaffy can buy up to 25,000 Medicus Pharma common shares at $0.50 if he chooses to exercise the options after they vest.

When do Patrick J. Mahaffy’s new Medicus Pharma (MDCX) options vest and expire?

The options become exercisable on March 26, 2027 and expire on March 27, 2031. After the expiration date, any unexercised options will lapse and can no longer be used to buy shares.

Is the Medicus Pharma (MDCX) Form 4 transaction a stock sale or purchase?

The Form 4 reflects a grant/award acquisition of stock options, not a market trade. Mahaffy did not buy or sell shares in the open market; he received options as part of his director compensation.

How many Medicus Pharma (MDCX) options does Patrick J. Mahaffy hold after this grant?

After the reported transaction, Mahaffy holds stock options for 25,000 common shares directly. These options give him the right, but not the obligation, to purchase those shares at $0.50 per share once exercisable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MAHAFFY PATRICK J

(Last) (First) (Middle)

300 CONSHOHOCKEN STATE ROAD

SUITE 200

(Street)

W. CONSHOHOCKEN PENNSYLVANIA 19428

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Medicus Pharma Ltd. [ MDCX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$0.5	03/30/2026		A		25,000		03/26/2027	03/27/2031	Common Shares	25,000	$0	25,000	D

Explanation of Responses:

	/s/ Raza Bokhari, as Attorney-in-Fact, for Patrick J. Mahaffy	04/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)